Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs IL-6 Inhibitor in Active ILD in Scleroderma
NCT05963048Phase 3Completed
- Sponsor
- Assiut University
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3 trial of rituximab and tocilizumab in interstitial lung disease (ILD) and scleroderma (2 arms), sponsored by Assiut University. Primary endpoint: Forced Vital Capacity at 6 months. Started Dec 2021; status: completed.
02
Drugs
rituximabtocilizumab
03
Conditions
interstitial lung disease (ILD)scleroderma
Beyond the preview
Go deeper on NCT05963048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05963048.